Omeros (OMER) Depreciation & Amortization (CF) (2010 - 2026)
Omeros (OMER) posted Depreciation & Amortization (CF) of $239000.0 for Q1 2026, up 1.7% sequentially from $235000.0 in Q4 2025, and down 17.3% YoY from $289000.0 in Q1 2025.
Powered by 
Analysis
Omeros (OMER) Depreciation & Amortization (CF) (2010 - 2026) Analysis & Trends
Omeros has reported Depreciation & Amortization (CF) for 17 years, with the latest figure at $239000.0 in Q1 2026.
- Quarterly Depreciation & Amortization (CF) fell 17.3% year-over-year to $239000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $914000.0 (down 11.69% YoY) and the FY2025 annual result came in at $964000.0, up 1.47% from the prior year.
- Depreciation & Amortization (CF) rose to $239000.0 in Q1 2026 per OMER's latest filing, from $235000.0 in the prior quarter.
- Over five years, Depreciation & Amortization (CF) peaked at $301000.0 in Q4 2024 and troughed at $163000.0 in Q4 2022.
- A 5-year average of $234235.3 and a median of $235000.0 in 2025 frame the typical range for Depreciation & Amortization (CF).
- The sharpest annual moves came in 2022 and 2023: Depreciation & Amortization (CF) plunged 50.0% in 2022, then soared 50.0% in 2023.
- Over 5 years, Depreciation & Amortization (CF) stood at $163000.0 in 2022, then gained by 25.77% to $205000.0 in 2023, then jumped by 46.83% to $301000.0 in 2024, then slipped by 21.93% to $235000.0 in 2025, then increased by 1.7% to $239000.0 in 2026.
- According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered $239000.0, $235000.0, and $240000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.43 Bn | 130.58 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 63.34 Bn | 58.15 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.98 Bn | 52.85 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 43.98 Bn | 43.98 Bn | - | - |
| 6 | BeOne Medicines | 39.92 Bn | 34.82 Bn | 1.53 Bn | 40.52 Mn |
| 7 | Alnylam Pharmaceuticals | 35.42 Bn | 32.11 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - | - |
| 9 | Insmed | 27.36 Bn | 26.20 Bn | 358.27 Mn | - |
| 10 | Omeros | 1.38 Bn | 1.38 Bn | 27.73 Mn | 193,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 193,000.00 |
| Mar 31, 2026 | 239,000.00 |
| Dec 31, 2025 | 235,000.00 |
| Sep 30, 2025 | 240,000.00 |
| Jun 30, 2025 | 200,000.00 |
| Mar 31, 2025 | 289,000.00 |
| Dec 31, 2024 | 301,000.00 |
| Sep 30, 2024 | 237,000.00 |
| Jun 30, 2024 | 208,000.00 |
| Mar 31, 2024 | 204,000.00 |
| Dec 31, 2023 | 205,000.00 |
| Sep 30, 2023 | 197,000.00 |
| Jun 30, 2023 | 300,000.00 |
| Mar 31, 2023 | 186,000.00 |
| Dec 31, 2022 | 163,000.00 |
| Sep 30, 2022 | 300,000.00 |
| Jun 30, 2022 | 200,000.00 |
| Mar 31, 2022 | 300,000.00 |
| Dec 31, 2021 | 286,000.00 |
| Sep 30, 2021 | 300,000.00 |